Ayala Pharmaceuticals, Inc. Logo

Ayala Pharmaceuticals, Inc.

AYLA

(1.2)
Stock Price

0,53 USD

-431.7% ROA

-560.23% ROE

-0.42x PER

Market Cap.

0,00 USD

-159.33% DER

0% Yield

-10089.8% NPM

Ayala Pharmaceuticals, Inc. Stock Analysis

Ayala Pharmaceuticals, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Ayala Pharmaceuticals, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (-7.51x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a minimal amount of debt (-159%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Graham Number

The Graham number of this company suggests that its stock price may be undervalued, indicating a potentially attractive investment opportunity.

4 ROE

Negative ROE (-308.79%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (-829.8%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

7 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Ayala Pharmaceuticals, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Ayala Pharmaceuticals, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Ayala Pharmaceuticals, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Ayala Pharmaceuticals, Inc. Revenue
Year Revenue Growth
2018 0
2019 2.334.000 100%
2020 3.708.000 37.06%
2021 0 0%
2022 420.000 100%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Ayala Pharmaceuticals, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2018 5.741.000
2019 14.424.000 60.2%
2020 22.406.000 35.62%
2021 29.941.000 25.17%
2022 30.288.000 1.15%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Ayala Pharmaceuticals, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2018 3.294.000
2019 4.336.000 24.03%
2020 7.371.000 41.17%
2021 9.277.000 20.55%
2022 8.624.000 -7.57%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Ayala Pharmaceuticals, Inc. EBITDA
Year EBITDA Growth
2018 -8.538.000
2019 -17.111.000 50.1%
2020 -29.483.000 41.96%
2021 -40.862.000 27.85%
2022 -70.812.000 42.3%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Ayala Pharmaceuticals, Inc. Gross Profit
Year Gross Profit Growth
2018 0
2019 1.049.000 100%
2020 0 0%
2021 -3.506.000 100%
2022 -152.000 -2206.58%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Ayala Pharmaceuticals, Inc. Net Profit
Year Net Profit Growth
2018 -8.873.000
2019 -17.792.000 50.13%
2020 -30.146.000 40.98%
2021 -38.702.000 22.11%
2022 -38.352.000 -0.91%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Ayala Pharmaceuticals, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2018 -1
2019 -2 50%
2020 -3 33.33%
2021 -4 0%
2022 -2 -50%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Ayala Pharmaceuticals, Inc. Free Cashflow
Year Free Cashflow Growth
2018 -6.592.000
2019 -16.280.000 59.51%
2020 -27.586.000 40.98%
2021 -38.361.000 28.09%
2022 -8.170.000 -369.53%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Ayala Pharmaceuticals, Inc. Operating Cashflow
Year Operating Cashflow Growth
2018 -6.371.000
2019 -14.950.000 57.38%
2020 -27.541.000 45.72%
2021 -38.356.000 28.2%
2022 -8.168.000 -369.59%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Ayala Pharmaceuticals, Inc. Capital Expenditure
Year Capital Expenditure Growth
2018 221.000
2019 1.330.000 83.38%
2020 45.000 -2855.56%
2021 5.000 -800%
2022 2.000 -150%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Ayala Pharmaceuticals, Inc. Equity
Year Equity Growth
2018 -21.859.000
2019 14.453.000 251.24%
2020 38.398.000 62.36%
2021 34.158.000 -12.41%
2022 -1.099.000 3208.1%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Ayala Pharmaceuticals, Inc. Assets
Year Assets Growth
2018 27.125.000
2019 20.054.000 -35.26%
2020 45.828.000 56.24%
2021 1.387.000 -3204.11%
2022 4.581.000 69.72%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Ayala Pharmaceuticals, Inc. Liabilities
Year Liabilities Growth
2018 48.984.000
2019 5.601.000 -774.56%
2020 7.430.000 24.62%
2021 497.000 -1394.97%
2022 5.680.000 91.25%

Ayala Pharmaceuticals, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.01
Net Income per Share
-1.28
Price to Earning Ratio
-0.42x
Price To Sales Ratio
0x
POCF Ratio
-0.47
PFCF Ratio
0
Price to Book Ratio
-7.51
EV to Sales
-3.35
EV Over EBITDA
0.02
EV to Operating CashFlow
0.04
EV to FreeCashFlow
0.04
Earnings Yield
-2.4
FreeCashFlow Yield
0
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
1.43
Graham NetNet
-0.21

Income Statement Metrics

Net Income per Share
-1.28
Income Quality
0.89
ROE
-5.6
Return On Assets
-4.32
Return On Capital Employed
9.36
Net Income per EBT
1.01
EBT Per Ebit
0.71
Ebit per Revenue
-141.15
Effective Tax Rate
-0.01

Margins

Sales, General, & Administrative to Revenue
25.72
Research & Developement to Revenue
75.35
Stock Based Compensation to Revenue
4.32
Gross Profit Margin
-0.19
Operating Profit Margin
-141.15
Pretax Profit Margin
-99.97
Net Profit Margin
-100.9

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-1.13
Free CashFlow per Share
-1.13
Capex to Operating CashFlow
0
Capex to Revenue
-0.01
Capex to Depreciation
-0.02
Return on Invested Capital
-11.62
Return on Tangible Assets
-4.32
Days Sales Outstanding
0
Days Payables Outstanding
4737.2
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0.08
Inventory Turnover
0
Capex per Share
-0

Balance Sheet

Cash per Share
0,16
Book Value per Share
-0,07
Tangible Book Value per Share
-0.07
Shareholders Equity per Share
-0.07
Interest Debt per Share
0.11
Debt to Equity
-1.59
Debt to Assets
0.38
Net Debt to EBITDA
0.02
Current Ratio
0.42
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
-1.59
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Ayala Pharmaceuticals, Inc. Dividends
Year Dividends Growth

Ayala Pharmaceuticals, Inc. Profile

About Ayala Pharmaceuticals, Inc.

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.

CEO
Dr. Roni Mamluk M.D., Ph.D.
Employee
35
Address
4 Oppenheimer Street
Rehovot, 7670104

Ayala Pharmaceuticals, Inc. Executives & BODs

Ayala Pharmaceuticals, Inc. Executives & BODs
# Name Age
1 Ms. Irit Klipper Avni M.A.
Vice President of HR
70
2 Mr. Yossi Maimon CPA, CPA, M.B.A., MBA
Chief Financial Officer, Sec. & Treasurer
70
3 Dr. Shmuel Tuvia Ph.D.
Chief Scientific Officer
70
4 Ms. Dana Gelbaum M.B.A., M.Sc.
Chief Bus. Officer
70
5 Dr. Roni Mamluk M.D., Ph.D.
Pres, Chief Executive Officer & Director
70
6 Dr. Gary B. Gordon M.D., Ph.D.
Chief Medical Officer
70

Ayala Pharmaceuticals, Inc. Competitors